Mary Seger - Concepedia

Author

Mary Seger

Eli Lilly (United States)

Also Known As

M SEGER, M Seger, M. Seger, Mary E Seger, Mary E. Seger, Mary Seger

Publications

751

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Eli Lilly (United Kingdom)Clinical Nutrition Research Centre Profil Institute for Metabolic Research Eli Lilly (Singapore)

About

Mary Seger is an author at Eli Lilly (United States) specializing in medicine, pharmacokinetics, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	173
2	Public Health	1	1	89
3	Biochemistry	1	1	68
4	Biostatistics	1	1	89
5	Diabetes	1	1	68

Mary Seger

Publications

737

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis William L. Macias, Jean-François Dhainaut, Sau Chi Betty Yan, Clinical Pharmacology & Therapeutics	2002	98
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies Helle Linnebjerg, Eric Chen Quin Lam, Mary Seger, Diabetes Care	2015	95
Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points Viswanath Devanarayan, Wendell C. Smith, Rocco L. Brunelle, The AAPS Journal VaccinationStatistical ComputingImmunophenotypingBiostatisticsPublic Health	2017	89
Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro Klaus Rave, Leszek Nosek, Amparo de la Peña, Diabetes Care	2005	75
Effect of age on the pharmacokinetics of duloxetine in women Michael Skinner, Han‐Yi Kuan, Andrej Skerjanec, British Journal of Clinical Pharmacology	2003	69
Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL Amparo de la Peña, Mary Seger, Danny Soon, Clinical Pharmacology in Drug Development Diabetes ManagementHealthy SubjectsBiochemistryMedicineInsulin Management	2015	68
Pharmacokinetic and glucodynamic comparisons of recombinant and animal‐source glucagon after IV, IM, and SC injection in healthy volunteers Casey J. Graf, James R. Woodworth, Mary Seger, Journal of Pharmaceutical Sciences	1999	33
A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects Helle Linnebjerg, Mary Seger, Prajakti A. Kothare, International Journal of Clinical Pharmacology and Therapeutics	2011	32
Intrahepatic portal vein sclerosis in patients without a history of liver disease. An autopsy study. Ian R. Wanless, V Bernier, Mary Seger PubMed	1982	32
Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial Prajakti A. Kothare, Mary Seger, Justin Northrup, BMC Clinical Pharmacology	2012	31

Page 1